Comparison of ASAP Score and GALAD Score in Detecting Hepatocellular Carcinoma in Chronic Liver Disease Patients with Different Etiologies

Comparison of ASAP Score and GALAD Score in Detecting Hepatocellular Carcinoma in Chronic Liver Disease Patients with Different Etiologies

2024.09.25
Primary liver cancer ranks as the fourth most common malignancy and the second leading cause of cancer-related deaths in China, posing a severe threat to people's lives and health. Early detection, diagnosis, and treatment are crucial for improving treatment outcomes. In 2019, Dr. Feng Shen and Dr. Tian Yang research team from Eastern Hepatobiliary Surgery Hospital, collaborating with 11 renowned tertiary hospitals in China, developed the ASAP (Alpha-Fetoprotein, Age, Sex, and PIVKA-II) liver cancer risk assessment model, making a significant contribution to Chinese clinical practice.
ESMO China’s Voice | Dr. Yuhong Zhou: Surufatinib Combined with Gemcitabine in Second-Line Treatment Shows Promise for Improving Prognosis in Soft Tissue Sarcoma

ESMO China’s Voice | Dr. Yuhong Zhou: Surufatinib Combined with Gemcitabine in Second-Line Treatment Shows Promise for Improving Prognosis in Soft Tissue Sarcoma

2024.09.24
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting recently concluded in Barcelona, Spain, bringing together the world's leading oncology experts. At this year's conference, Dr. Yuhong Zhou from Zhongshan Hospital, Fudan University, presented a phase II multicenter clinical trial that explored the efficacy and safety of surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients who had failed anthracycline chemotherapy or anlotinib monotherapy. The study offers new perspectives for clinical practice.
ESMO On-site Highlights | Dr. Shukui Qin’s LBA Study Breakthrough: DUBHE-H-308 Offers New Options for First-Line Liver Cancer Treatment

ESMO On-site Highlights | Dr. Shukui Qin’s LBA Study Breakthrough: DUBHE-H-308 Offers New Options for First-Line Liver Cancer Treatment

2024.09.24
From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. At this prestigious conference, the DUBHE-H-308 study led by Dr. Shukui Qin from Nanjing Tianyinshan Hospital, affiliated with China Pharmaceutical University, was selected for an LBA oral presentation (Abstract No.: LBA38). On September 13, from 16:00 to 16:10 local time, Dr. Shukui Qin presented the study online. Oncology Frontier attended the event and compiled the key findings of this significant research for readers.
ESMO China’s Voice | Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: Using Personalized ctDNA Methylation Haplotypes to Monitor Minimal Residual Disease After Curative Resection for Liver Cancer

ESMO China’s Voice | Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: Using Personalized ctDNA Methylation Haplotypes to Monitor Minimal Residual Disease After Curative Resection for Liver Cancer

2024.09.24
The ESMO Annual Meeting 2024, held from September 13 to 17 in Barcelona, Spain, showcased the latest breakthroughs in oncology. Among them was a new study from the team led by Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang from Zhongshan Hospital, Fudan University, in collaboration with Burning Rock Biotech. The research, which was presented as a poster at the conference, provided preliminary evidence that the methylation and mutation of circulating tumor DNA (ctDNA) play a crucial role in assessing minimal residual disease (MRD) status and predicting recurrence after curative liver cancer surgery. This study offers new strategies and tools for postoperative management of early-stage liver cancer patients. With further refinement and large-scale clinical validation, this method could become an important adjunct in postoperative monitoring, potentially improving patient survival outcomes.
Exclusive Interview with Dr. Huilai Zhang: A Detailed Look at the 5th Tianjin International Lymphoma Conference

Exclusive Interview with Dr. Huilai Zhang: A Detailed Look at the 5th Tianjin International Lymphoma Conference

2024.09.23
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform that fosters international academic exchange and cooperation. During the event, Hematology Frontier had the privilege of interviewing the conference chair, Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital. He shared insights into the highlights of the conference and the future development of lymphoma research.
Dr. Robert Negrin: An In-Depth Analysis of Immunomodulatory Mechanisms and Transplantation

Dr. Robert Negrin: An In-Depth Analysis of Immunomodulatory Mechanisms and Transplantation

2024.09.23
In the field of hematopoietic stem cell transplantation (HSCT), immunomodulatory mechanisms play a crucial role, affecting not only the success rate of the transplant but also the recipient's tolerance to the graft and their long-term health post-transplant. At the 12th Lu Daopei Hematology Academic Forum, Dr. Robert Negrin, former Chief of the Blood and Marrow Transplantation at Stanford University, shared a fascinating lecture on immunomodulatory mechanisms and transplantation. "Hematology Frontier" specially invited Dr. Robert Negrin for an exclusive interview, providing us with an international perspective on cutting-edge topics such as graft-versus-host disease (GVHD), graft-versus-tumor effect (GVT), and immune tolerance.
ESMO 2024 | Dr. Gabriella Pravettoni: Physical Activity is Beneficial for Cancer Patients, But Also Challenging

ESMO 2024 | Dr. Gabriella Pravettoni: Physical Activity is Beneficial for Cancer Patients, But Also Challenging

2024.09.23
Evidence from the Breast Cancer Customization Project suggests that a more comprehensive approach is needed to help patients find the motivation to adopt an active lifestyle. Physical activity is often recommended by clinicians as a lifestyle intervention to help prevent and manage non-communicable diseases, including cancer. It is also essential for the quality of life of patients diagnosed with cancer.